Bluejay Diagnostics (BJDX) Net Income towards Common Stockholders (2020 - 2026)
Bluejay Diagnostics recorded quarterly Net Income towards Common Stockholders of -$1.9 million in Q1 2026, down 34.28% quarter-over-quarter from -$1.4 million in Q4 2025, and down 2.61% year-over-year from -$2.0 million in Q1 2025.
Bluejay Diagnostics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$1.9 million for Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 2.61% year-over-year to -$1.9 million; the TTM figure through Mar 2026 stood at -$6.9 million (up 66.35% YoY), while the FY2025 annual figure was -$6.8 million, up 67.3% from the prior year.
- Net Income towards Common Stockholders came in at -$1.9 million for Q1 2026 at Bluejay Diagnostics, down from -$1.4 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.4 million in Q4 2025 to a low of -$14.7 million in Q3 2024.
- A 5-year average of -$2.9 million and a median of -$2.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders plunged 786.91% in 2022 and surged 89.14% in 2025, its largest moves.
- Bluejay Diagnostics' Net Income towards Common Stockholders stood at -$2.5 million in 2022, then advanced by 2.73% to -$2.4 million in 2023, then soared by 40.0% to -$1.4 million in 2024, then rose by 0.15% to -$1.4 million in 2025, then sank by 34.28% to -$1.9 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$1.9 million, -$1.4 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.15 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 187,319.30 |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 199.50 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - | -1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.92 Mn |
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.60 Mn |
| Jun 30, 2025 | -1.96 Mn |
| Mar 31, 2025 | -1.87 Mn |
| Dec 31, 2024 | -1.43 Mn |
| Sep 30, 2024 | -14.71 Mn |
| Jun 30, 2024 | -2.51 Mn |
| Mar 31, 2024 | -2.40 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | -2.34 Mn |
| Jun 30, 2023 | -2.90 Mn |
| Mar 31, 2023 | -2.68 Mn |
| Dec 31, 2022 | -2.45 Mn |
| Sep 30, 2022 | -2.81 Mn |
| Jun 30, 2022 | -1.99 Mn |
| Mar 31, 2022 | -2.07 Mn |
| Dec 31, 2021 | -1.37 Mn |
| Sep 30, 2021 | -957,988.00 |
| Jun 30, 2021 | -666,072.00 |
| Mar 31, 2021 | -233,198.00 |
| Dec 31, 2020 | -581,779.00 |
| Sep 30, 2020 | -148,169.00 |